Cell Gene Therapy Biomanufacturing Market Summary

As per Market Research Future analysis, the Cell and Gene Therapy Biomanufacturing Market was estimated at 17.05 USD Billion in 2024. The market is projected to grow from 18.85 USD Billion in 2025 to 51.65 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Cell and Gene Therapy Biomanufacturing Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

North America remains the largest market for cell and gene therapy biomanufacturing, reflecting robust investment and infrastructure.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing healthcare expenditures and innovation.
Cell therapy continues to dominate the market, while gene therapy is recognized as the fastest-growing segment due to its transformative potential.
Key drivers include the rising prevalence of genetic disorders and advancements in biomanufacturing technologies, which are shaping market dynamics.

Market Size & Forecast

2024 Market Size	17.05 (USD Billion)
2035 Market Size	51.65 (USD Billion)
CAGR (2025 - 2035)	10.6%

Major Players

Novartis (CH), Gilead Sciences (US), Bristol-Myers Squibb (US), Amgen (US), Sangamo Therapeutics (US), Bluebird Bio (US), Celyad Oncology (BE), Spark Therapeutics (US), CRISPR Therapeutics (CH)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Cell Gene Therapy Biomanufacturing Market Trends

The Cell and Gene Therapy Biomanufacturing Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and increasing investments. This sector is witnessing a surge in demand for innovative therapies that address previously untreatable conditions. As regulatory frameworks evolve, companies are adapting their manufacturing processes to ensure compliance while maintaining efficiency. The integration of automation and artificial intelligence is streamlining production, enhancing quality control, and reducing costs. Furthermore, collaborations between academic institutions and industry players are fostering research and development, leading to novel therapeutic solutions. In addition, the Cell and Gene Therapy Biomanufacturing Market is likely to benefit from a growing emphasis on personalized medicine. Tailored therapies that cater to individual patient needs are becoming more prevalent, driving the need for flexible manufacturing capabilities. The market appears poised for expansion as stakeholders recognize the potential of these therapies to revolutionize treatment paradigms. Overall, the landscape is dynamic, with ongoing innovations and strategic partnerships shaping the future of biomanufacturing in this field.

Technological Advancements

The Cell and Gene Therapy Biomanufacturing Market is witnessing significant technological innovations that enhance production efficiency. Automation and advanced analytics are being integrated into manufacturing processes, allowing for real-time monitoring and quality assurance. These advancements not only streamline operations but also reduce the likelihood of human error, thereby improving overall product quality.

Regulatory Evolution

As the Cell and Gene Therapy Biomanufacturing Market matures, regulatory bodies are adapting their frameworks to accommodate new therapies. This evolution is crucial for ensuring patient safety while fostering innovation. Companies are increasingly focusing on compliance strategies that align with these changing regulations, which may influence their manufacturing practices and timelines.

Personalized Medicine Focus

The shift towards personalized medicine is becoming a defining trend within the Cell and Gene Therapy Biomanufacturing Market. Therapies tailored to individual genetic profiles are gaining traction, necessitating flexible manufacturing solutions. This trend indicates a move away from traditional one-size-fits-all approaches, potentially leading to improved patient outcomes and satisfaction.

Cell Gene Therapy Biomanufacturing Market Drivers

Regulatory Support for Gene Therapies

Regulatory bodies are increasingly supportive of gene therapies, which is positively impacting the Cell and Gene Therapy Biomanufacturing Market. Initiatives aimed at expediting the approval process for innovative therapies are being implemented, allowing companies to bring their products to market more swiftly. For example, the introduction of breakthrough therapy designations and accelerated approval pathways has encouraged investment in gene therapy development. This regulatory environment not only fosters innovation but also enhances the confidence of investors and stakeholders in the biomanufacturing sector. As regulations continue to evolve, they are likely to create a more favorable landscape for the growth of the market.

Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders is a primary driver for the Cell and Gene Therapy Biomanufacturing Market. As more individuals are diagnosed with conditions such as hemophilia, cystic fibrosis, and muscular dystrophy, the demand for innovative therapies rises. According to recent estimates, genetic disorders affect approximately 1 in 10 individuals, leading to a significant need for effective treatment options. This growing patient population necessitates advancements in biomanufacturing processes to produce therapies at scale. Furthermore, the shift towards gene therapies that target the root causes of these disorders is likely to propel investments in biomanufacturing capabilities, thereby enhancing the overall market landscape.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is a significant driver for the Cell and Gene Therapy Biomanufacturing Market. Patients increasingly seek treatments tailored to their unique genetic profiles, which necessitates the development of bespoke therapies. This trend is evident in the rising number of clinical trials focused on gene therapies that address specific genetic mutations. The market for personalized medicine is projected to grow substantially, with estimates suggesting a compound annual growth rate of over 10% in the coming years. As the demand for individualized treatments escalates, biomanufacturers are likely to adapt their processes to meet these needs, thereby enhancing their market position.

Advancements in Biomanufacturing Technologies

Technological innovations in biomanufacturing are transforming the Cell and Gene Therapy Biomanufacturing Market. The introduction of automated systems, improved cell culture techniques, and enhanced vector production methods are streamlining the manufacturing process. For instance, the adoption of single-use bioreactors has been shown to reduce production costs and time, making therapies more accessible. Additionally, advancements in CRISPR and other gene-editing technologies are facilitating the development of more precise and effective therapies. As these technologies continue to evolve, they are expected to drive efficiency and scalability in biomanufacturing, ultimately expanding the market's potential.

Increased Investment in Research and Development

Investment in research and development is a crucial driver for the Cell and Gene Therapy Biomanufacturing Market. Pharmaceutical companies and biotech firms are allocating substantial resources to explore novel therapies and improve existing ones. In recent years, R&D spending in the biopharmaceutical sector has surged, with estimates indicating a growth rate of over 5% annually. This influx of capital is fostering innovation in biomanufacturing processes, enabling the production of more complex and effective therapies. As companies strive to bring new products to market, the demand for advanced biomanufacturing solutions is likely to increase, further propelling market growth.

Market Segment Insights

By Therapy Type: Cell Therapy (Largest) vs. Gene Therapy (Fastest-Growing)

The The Cell and Gene Therapy Biomanufacturing sector is primarily driven by advancements in cell therapy. is primarily driven by advancements in cell therapy, which currently holds the largest segment share. Cell therapy's established methodologies and extensive clinical applications contribute to its leading position, trusted by healthcare providers and patients alike. Meanwhile, gene therapy is emerging swiftly, showing the greatest potential for development and implementation in upcoming years, as innovations pave the way for diseases previously deemed untreatable. The growth trends in this market are largely influenced by increasing investments in biotechnology research and advancements in genomic technologies. Companies focusing on the development of novel gene therapies are expanding their pipelines, reflecting a significant upsurge in clinical research activities. The need for effective treatments in rare diseases and genetic disorders continues to fuel this growth, reinforcing gene therapy's swift ascent in the biomanufacturing landscape.

Therapy Type: Cell Therapy (Dominant) vs. Combined Therapy (Emerging)

Cell therapy represents the dominant force in the Cell and Gene Therapy Biomanufacturing Market, characterized by its ability to restore or replace dysfunctional cells. This segment has been well-established in the market, recognized for its applications in cancer treatment, autoimmune disorders, and regenerative medicine. With robust supply chains and regulatory pathways firmly in place, cell therapy is well-positioned for continued expansion. On the other hand, combined therapy is viewed as an emerging segment, integrating both cell and gene therapeutic approaches. This strategy has the potential to enhance treatment efficacy and overcome the limitations of single-modality therapies, thus attracting considerable attention from biomanufacturers looking to innovate in multi-faceted treatment solutions.

By Product Type: Reagents (Largest) vs. Equipment (Fastest-Growing)

In the In the Cell and Gene Therapy Biomanufacturing sector, the segment of Reagents holds the largest market share., the segment of Reagents holds the largest market share, representing a significant portion of the overall landscape. This dominance is largely attributed to the critical role reagents play in various stages of biomanufacturing processes, including cell culture and genetic modification. On the other hand, the Equipment segment is rapidly gaining traction, driven by technological advancements and an increasing need for sophisticated manufacturing capabilities.

Equipment (Dominant) vs. Media (Emerging)

The Equipment segment is a dominant force within the Cell and Gene Therapy Biomanufacturing Market, characterized by its advanced machinery and tools that enhance production efficiency and scalability. This segment includes bioprocessing systems, cell expansion devices, and analytical instruments, which are crucial for ensuring the quality and efficacy of gene therapies. In contrast, the Media segment is emerging as increasingly significant, as it provides the necessary nutrients and environment for cell proliferation and maintenance. The demand for specialized media formulations is on the rise as companies seek to optimize cell growth conditions and improve product yield, indicating strong potential for future growth.

By Technology: Viral Vector Technology (Largest) vs. Non-Viral Vector Technology (Fastest-Growing)

In the In the Cell and Gene Therapy Biomanufacturing sector, the technology segment is characterized by distinctive elements., the technology segment is characterized by distinctive elements, with Viral Vector Technology holding the largest market share. This technology has dominated the landscape due to its well-established methodologies and significant application in developing gene therapies. Conversely, Non-Viral Vector Technology, while not the largest, is gaining momentum and is recognized as the fastest-growing segment, benefiting from ongoing research and advancements that promote its adoption in therapeutic applications. Recent trends indicate a shift towards a more diverse range of technologies in gene therapy, driven by innovations and emerging needs in the market. Non-Viral Vector Technology is witnessing rapid growth, supported by its flexibility and lower immunogenic profiles compared to viral vectors. As the focus shifts toward personalized medicine, both technologies are expected to evolve, catering to new treatment modalities, thereby enhancing patient outcomes in the biomanufacturing process.

Technology: Viral Vector (Dominant) vs. Non-Viral Vector (Emerging)

Viral Vector Technology remains the dominant force in the Cell and Gene Therapy Biomanufacturing Market, recognized for its efficacy in delivering genetic material into target cells. This technology utilizes modified viruses to carry therapeutic genes, making it essential for the development of advanced gene therapies. Its well-established presence enables a robust framework for successful therapeutic interventions. In contrast, Non-Viral Vector Technology is emerging strongly, appealing to developers due to its advantages, including safety and lower production costs. This segment leverages methods such as electroporation and lipofection, enabling researchers to expand their therapeutic options. The growth in this area is indicative of a broader trend toward innovative solutions that complement established methodologies, thus fostering a competitive landscape in biomanufacturing.

By End User: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the In the Cell and Gene Therapy Biomanufacturing sector, the end-user segment is predominantly driven by pharmaceutical companies., the end-user segment is predominantly driven by pharmaceutical companies, which hold the largest market share due to their extensive research, development capabilities, and established distribution channels. Following closely are biotechnology companies, which are gaining significant traction as they innovate rapidly and cater to niche markets, reflecting a growing shift towards tailored therapeutic solutions. Academic research institutes also play a crucial role, providing foundational research but command a smaller portion of the overall market.

Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging)

Pharmaceutical companies are at the forefront of the Cell and Gene Therapy Biomanufacturing Market, leveraging their vast resources, advanced R&D capabilities, and regulatory expertise to dominate the sector. They typically drive the pace of innovation and bring a wealth of experience in large-scale production and commercialization. Conversely, biotechnology companies are emerging rapidly, characterized by their agility and focus on novel therapies that target specific patient needs. Their ability to develop unique solutions for complex diseases positions them as crucial players in the market, appealing to both investors and patients seeking cutting-edge treatment options.

Get more detailed insights about Cell Gene Therapy Biomanufacturing Market

Request Free Sample

Regional Insights

The Cell and Gene Therapy Biomanufacturing Market exhibited a promising growth trajectory driven by its diverse regional dynamics.

In 2024, the market was valued at 9.59 USD Billion, with North America holding the majority share at 4.45 USD Billion. This dominance was attributed to advanced biomanufacturing infrastructure, significant Research and Development investment, and a favorable regulatory environment.

Europe followed with a valuation of 2.75 USD Billion in the same year, propelled by strong collaborations between academia and industries. The Asia-Pacific (APAC) region, valued at 1.8 USD Billion, demonstrated rapid growth potential due to increasing healthcare funding and technological adoption.

South America and the Middle East and Africa (MEA) were smaller markets, valued at 0.4 USD Billion and 0.19 USD Billion respectively in 2024. However, both regions presented significant opportunities for market expansion as investments grow in healthcare innovations.

By 2035, the market is projected to reach 25.0 USD Billion, with North America continuing to lead, while the APAC region shows remarkable growth potential, highlighting the increasing global focus on cell and gene therapies. The Cell and Gene Therapy Biomanufacturing Market statistics reflected a blend of established markets and emerging opportunities, driving a competitive landscape across regions.

Source Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Cell Gene Therapy Biomanufacturing Market Regional Image

Key Players and Competitive Insights

The Cell and Gene Therapy Biomanufacturing Market is characterized by rapid advancements and competitive dynamics driven by innovation and growing demand for personalized medicine solutions. As industry evolves, companies strive to enhance their manufacturing capabilities, aiming to produce cell and gene therapies that are not only effective but also cost-efficient. The competitive landscape is marked by partnerships, strategic collaborations, and mergers that enable companies to leverage their unique strengths and technologies. Furthermore, the ongoing regulatory development and increased funding have stimulated market growth, ushering in new entrants and intensifying competition among established players, all striving to gain market share in this burgeoning field. Lonza has established itself as a formidable player within the Cell and Gene Therapy Biomanufacturing Market, primarily through its extensive expertise in bioprocessing and manufacturing services. The company’s strengths lie in its ability to provide a comprehensive range of customizable manufacturing solutions that cater to the specific needs of its clients in the cell and gene therapy sectors. With state-of-the-art facilities and a robust supply chain, Lonza is well-positioned to meet the high-quality standards required in this nuanced market. Additionally, the company’s proactive investment in technology and its commitment to innovation enable it to stay ahead of emerging trends, hence bolstering its competitive edge. Lonza's global reach allows it to tap into diverse markets across regions, facilitating widespread distribution and collaboration with a variety of stakeholders, including biotech firms and research institutions. Pfizer has made significant inroads into the Cell and Gene Therapy Biomanufacturing Market through its robust portfolio of advanced therapies and biomanufacturing capabilities. With a focus on groundbreaking products and services that align with the evolving needs of the market, Pfizer’s strengths include its extensive research background, scalability, and technological innovations. The company has pursued strategic mergers and acquisitions to bolster its competencies in cell and gene therapy biomanufacturing, allowing Pfizer to integrate cutting-edge technologies and expand its operational capacity. Their commitment to product development is complemented by a solid global presence, enabling collaborations with various stakeholders in the healthcare ecosystem. Pfizer's proactive engagement in clinical trials and demonstrations of their therapies enhances their reputation and positioning in the market, further establishing them as a key contributor in the field of cell and gene therapies on a global scale.

Key Companies in the Cell Gene Therapy Biomanufacturing Market include

Industry Developments

Recent developments in the Cell and Gene Therapy Biomanufacturing Market have seen significant advancements, particularly as major players focus on enhancing production capabilities and pursuing strategic collaborations.

Notably, Lonza has ramped up its manufacturing efforts to support gene therapy projects, while Pfizer has expanded its footprint in gene therapies, reflecting its growing commitment to the sector. In addition to these expansions, Thermo Fisher Scientific has been at the forefront of providing innovative biomanufacturing solutions, contributing to overall market development.

In terms of mergers and acquisitions, Roche made a substantial move by acquiring Spark Therapeutics in March 2019, bolstering its gene therapy portfolio. Furthermore, Samsung Biologics announced the purchase of a biopharmaceutical plant to enhance its capabilities in cell therapy production in January 2022.

The market has been buoyed by increased investment and RD activities, with companies like Bristol Myers Squibb and Novartis continually pushing boundaries in gene therapy research.

As of October 2023, the cumulative investments in this sector highlight the critical role of these companies in shaping the future of biomanufacturing, reinforcing the pivotal role that cell and gene therapies play in global healthcare advancements.

Future Outlook

Cell Gene Therapy Biomanufacturing Market Future Outlook

The Cell and Gene Therapy Biomanufacturing Market is projected to grow at a 10.6% CAGR from 2025 to 2035, driven by technological advancements, regulatory support, and increasing demand for personalized medicine.

New opportunities lie in:

Investment in automated bioreactor systems for enhanced production efficiency.
Development of modular cleanroom facilities to reduce setup costs.
Partnerships with logistics firms for optimized supply chain management.

By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

Market Segmentation

Cell Gene Therapy Biomanufacturing Market End User Outlook

Pharmaceutical Companies
Biotechnology Companies
Academic Research Institutes

Cell Gene Therapy Biomanufacturing Market Technology Outlook

Viral Vector Technology
Non-Viral Vector Technology
Cell Processing Technology

Cell Gene Therapy Biomanufacturing Market Product Type Outlook

Reagents
Equipment
Media

Cell Gene Therapy Biomanufacturing Market Therapy Type Outlook

Cell Therapy
Gene Therapy
Combined Therapy

Report Scope

MARKET SIZE 2024	17.05(USD Billion)
MARKET SIZE 2025	18.85(USD Billion)
MARKET SIZE 2035	51.65(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	10.6% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Novartis (CH), Gilead Sciences (US), Bristol-Myers Squibb (US), Amgen (US), Sangamo Therapeutics (US), Bluebird Bio (US), Celyad Oncology (BE), Spark Therapeutics (US), CRISPR Therapeutics (CH)
Segments Covered	Therapy Type, Product Type, Technology, End User, Regional
Key Market Opportunities	Advancements in automation and process optimization enhance efficiency in the Cell and Gene Therapy Biomanufacturing Market.
Key Market Dynamics	Rising demand for personalized medicine drives innovation and competition in cell and gene therapy biomanufacturing.
Countries Covered	North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2035?

The projected market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2035 is 51.65 USD Billion.

What was the market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2024?

The market valuation for the Cell and Gene Therapy Biomanufacturing Market in 2024 was 17.05 USD Billion.

What is the expected CAGR for the Cell and Gene Therapy Biomanufacturing Market from 2025 to 2035?

The expected CAGR for the Cell and Gene Therapy Biomanufacturing Market during the forecast period 2025 - 2035 is 10.6%.

Which companies are considered key players in the Cell and Gene Therapy Biomanufacturing Market?

Key players in the market include Novartis, Gilead Sciences, Bristol-Myers Squibb, Amgen, Sangamo Therapeutics, Bluebird Bio, Celyad Oncology, Spark Therapeutics, and CRISPR Therapeutics.

What are the projected valuations for Cell Therapy and Gene Therapy segments by 2035?

By 2035, the projected valuation for Cell Therapy is 19.5 USD Billion, while Gene Therapy is expected to reach 22.5 USD Billion.

How do the product types in the Cell and Gene Therapy Biomanufacturing Market compare in terms of projected growth?

In 2035, Reagents are projected to reach 15.5 USD Billion, Equipment 18.6 USD Billion, and Media 17.55 USD Billion.

What is the expected growth for Viral Vector Technology in the Cell and Gene Therapy Biomanufacturing Market by 2035?

Viral Vector Technology is projected to grow to 19.5 USD Billion by 2035.

What is the anticipated market size for Biotechnology Companies as end users by 2035?

The anticipated market size for Biotechnology Companies as end users is expected to reach 21.0 USD Billion by 2035.

What segment is projected to have the highest valuation in the Cell and Gene Therapy Biomanufacturing Market by 2035?

Gene Therapy is projected to have the highest valuation in the market, reaching 22.5 USD Billion by 2035.

How does the market for Academic Research Institutes compare to Pharmaceutical Companies in 2035?

In 2035, the market for Academic Research Institutes is expected to reach 11.15 USD Billion, whereas Pharmaceutical Companies are projected to reach 19.5 USD Billion.

Author

Author

Nidhi Mandole

Senior Research Analyst

She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Co-Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment